Literature DB >> 19618006

Sublingual misoprostol for the prevention of postpartum hemorrhage.

Abdelrahman H Al-Harazi1, Kaima A Frass.   

Abstract

OBJECTIVE: To compare the effectiveness of misoprostol (600 microg) when administered sublingually with the same dose administered per rectum to patients, immediately after delivery in preventing postpartum hemorrhage (PPH).
METHODS: This study was carried out in Al Thawra General Hospital, Sana'a, Yemen, from May 1, 2007 to April 31, 2008. A total of 215 women were recruited, and divided into 2 groups in a quasi-random fashion. Group I comprised 118 women, and was given 600 ug misoprostol sublingually immediately after delivery. The other group comprised 97 women (group II), and was given the same dose of misoprostol per rectum. The blood loss was measured, and the side effects of the misoprostol were assessed. The need for additional uterotonic agents, blood transfusion, and the length of the third stage labor were recorded.
RESULTS: Nine patients in group I, and 7 patients in group II had PPH. Of these patients, blood loss was >1000 ml in 4 patients in group I, but <1500 ml in 3 patients in group II, (relative risk - 1.05, 0.40 - 2.73 confidence interval [95%]. The mean blood loss was 362.3 +/- 170 ml in group I versus 342.3 +/- 154.7 ml in group II. Only 3 cases (3%) of the patients in group I were given additional uterotonic agents versus 2 cases (2%) in group II.
CONCLUSION: Postpartum use of 600 microg misoprostol by sublingual route has a comparable effect in reducing PPH, as that of rectal route. It was observed that severe PPH (1000 ml but <1500 ml) had been observed in 40% of those who developed PPH in both groups.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19618006

Source DB:  PubMed          Journal:  Saudi Med J        ISSN: 0379-5284            Impact factor:   1.484


  7 in total

Review 1.  Prostaglandins for preventing postpartum haemorrhage.

Authors:  Özge Tunçalp; G Justus Hofmeyr; A Metin Gülmezoglu
Journal:  Cochrane Database Syst Rev       Date:  2012-08-15

2.  Randomised Controlled Trial of Sublingual and Rectal Misoprostol in the Prevention of Primary Postpartum Haemorrhage in a Resource-Limited Community.

Authors:  Jacob Olumuyiwa Awoleke; Benedict Tolulope Adeyanju; Adebayo Adeniyi; Olusola Peter Aduloju; Babatunde Ajayi Olofinbiyi
Journal:  J Obstet Gynaecol India       Date:  2020-06-29

3.  Dose and side effects of sublingual misoprostol for treatment of postpartum hemorrhage: what difference do they make?

Authors:  Wilfrido León; Jill Durocher; Gustavo Barrera; Ernesto Pinto; Beverly Winikoff
Journal:  BMC Pregnancy Childbirth       Date:  2012-07-07       Impact factor: 3.007

4.  Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis.

Authors:  Ioannis D Gallos; Argyro Papadopoulou; Rebecca Man; Nikolaos Athanasopoulos; Aurelio Tobias; Malcolm J Price; Myfanwy J Williams; Virginia Diaz; Julia Pasquale; Monica Chamillard; Mariana Widmer; Özge Tunçalp; G Justus Hofmeyr; Fernando Althabe; Ahmet Metin Gülmezoglu; Joshua P Vogel; Olufemi T Oladapo; Arri Coomarasamy
Journal:  Cochrane Database Syst Rev       Date:  2018-12-19

5.  Sublingual misoprostol and hyperpyrexia: case report with temperature curve.

Authors:  Paul Nkemtendong Tolefac; Jacqueline Ze Minkande
Journal:  BMC Res Notes       Date:  2017-07-26

Review 6.  Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis.

Authors:  Ioannis D Gallos; Helen M Williams; Malcolm J Price; Abi Merriel; Harold Gee; David Lissauer; Vidhya Moorthy; Aurelio Tobias; Jonathan J Deeks; Mariana Widmer; Özge Tunçalp; Ahmet Metin Gülmezoglu; G Justus Hofmeyr; Arri Coomarasamy
Journal:  Cochrane Database Syst Rev       Date:  2018-04-25

7.  Feasibility, acceptability, and programme effectiveness of misoprostol for prevention of postpartum haemorrhage in rural bangladesh: a quasiexperimental study.

Authors:  Abdul Quaiyum; Rukhsana Gazi; Shahed Hossain; Andrea Wirtz; Nirod Chandra Saha
Journal:  Int J Reprod Med       Date:  2014-04-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.